🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
18,156
Companies
1,062
Drugs tracked
3,187

Quick answer

NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

249 results for “ISTA” Clear

  1. MaaT013

    Pharma Mar S.A.

    Treatment of acute graft-versus host disease (aGvHD) to the gastrointestinal (GI) tract of patients who are resistant or intolerant to ruxolitinib.

    phase 3 small molecule active

    1 trial

  2. Medical Air, KALINOX 50%/50%, gaz médicinal comprimé

    Tour Hekla

    Resistant Depression in the Elderly Subject

    phase 3 small molecule active

    1 trial

  3. Metformina Uxa 850 mg comprimidos recubiertos con película EFG, El producto denominado Placebo Metformina comprimidos recubiertos está constituido por comprimidos recubiertos blancos que contienen celulosa microcristalina Ph Eur, acondicionados en blisters de PVC/PE/PVDC transparente con aluminio anónimo.

    Institut für biomedizinische Analytik NMR-Imaging GmbH

    Chronic Obstructive Pulmonary Disease (COPD)

    phase 3 small molecule active

    1 trial

  4. NICOTINAMIDE, cellulose microcristalline

    ISTA Pharma Limited

    Acute kidney injury

    phase 3 small molecule active

    1 trial

  5. Opevesostat, FLUDROCORTISONE, PREDNISOLONE, DEXAMETHASONE ACETATE, HYDROCORTISONE, FLUDROCORTISONE ACETATE, ABIRATERONE ACETATE, DEXAMETHASONE, ABIRATERONE ACETATE, HYDROCORTISONE, HYDROCORTISONE, ENZALUTAMIDE, HYDROCORTISONE, PREDNISONE, PREDNISONE ACETATE, HYDROCORTISONE

    Merck Sharp and Dohme

    Metastatic castration resistant prostate cancer

    phase 3 small molecule active

    1 trial

  6. PACLITAXEL, ALPELISIB, DOXORUBICIN HYDROCHLORIDE, OLAPARIB, ALPELISIB, OLAPARIB

    Novartis Ophthalmics Europe

    Platinum-resistant or refractory, high-grade serous ovarian cancer with no germline BRCA mutation

    phase 3 small molecule active

    1 trial

  7. PACLITAXEL, Raludotatug Deruxtecan, TOPOTECAN, DOXORUBICIN HYDROCHLORIDE, LIPOSOMAL

    Daiichi Sankyo Europe GmbH

    Platinum-resistant, high-grade serous ovarian cancer (OVC),high-grade endometrioid OVC, primary peritoneal cancer, or fallopian tube cancer

    phase 3 small molecule active

    1 trial

  8. PEGFILGRASTIM , PACLITAXEL , DOXORUBICIN , Rinatabart Sesutecan, GEMCITABINE , TOPOTECAN

    Genmab A/S

    Platinum-resistant Ovarian Cancer

    phase 3 small molecule active

    1 trial

  9. PF-06821497, Tablet to match Placebo for PF-06821497 250mg, PF-06821497, ENZALUTAMIDE, Tablet to match Placebo for PF-06821497 125mg

    Pfizer Ireland Pharmaceuticals Unlimited Company

    METASTATIC CASTRATION RESISTANT PROSTATE CANCER

    phase 3 small molecule active

    1 trial

  10. PH94B

    Vistagen Therapeutics

    Social Anxiety Disorder

    phase 3 small molecule terminated

    1 trial

  11. PH94B Nasal Spray

    Vistagen Therapeutics

    Social Anxiety Disorder

    phase 3 small molecule terminated

    2 trials

  12. PREDNISOLONE , PREDNISONE , -, Ifinatamab Deruxtecan, PARACETAMOL , -, DOCETAXEL , -, -, -

    Merck Sharp and Dohme

    Metastatic Castration-Resistant Prostate Cancer

    phase 3 small molecule active

    1 trial

  13. PREDNISONE, BMS-986365, ENZALUTAMIDE, ABIRATERONE, DOCETAXEL, PREDNISOLONE, ABIRATERONE, ENZALUTAMIDE

    Celgene Europe Limited

    Metastatic Castration-resistant Prostate Cancer (mCRPC)

    phase 3 small molecule active

    1 trial

  14. Placebo

    Kalvista Pharmaceuticals (Ireland) Limited

    Hereditary Angioedema

    phase 3 small molecule completed

    1 trial

  15. Placebo JNJ-78278343, Placebo JNJ-78278343, JNJ-78278343, JNJ-78278343

    Janssen-Cilag International N.V.

    Metastatic Castration-resistant Prostate Cancer (mCRPC)

    phase 3 small molecule active

    1 trial

  16. Placebo to capivasertib, Capivasertib, Bendadocel 20 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Docetaxel Accord 80 mg/4 ml concentrate for solution for infusion, Capivasertib, Docetaxel Hikma 80 mg/4 ml Konzentrat zur Herstellung einer Infusionslösung

    AstraZeneca AB

    Metastatic Castration Resistant Prostate Cancer (mCRPC)

    phase 3 small molecule active

    1 trial

  17. Placebo, capsule, ZYTIGA 500 mg film-coated tablets, Prednison acis 5 mg, Tabletten, Fuzuloparib

    Pharma Mar S.A.

    Metastatic Castration-Resistant Prostate Cancer

    phase 3 small molecule active

    1 trial

  18. Privigen 100 mg/ml solution for infusion, Fortecortin® 2 mg Tabletten, Dexamethason 8 mg GALEN® Tabletten, Privigen 100 mg/ml solution for infusion, teclistamab, JNJ-64407564, Pomalidomide, Dexamethasone Tablets BP 2.0mg, Imnovid 3 mg hard capsules, Pomalidomide, Imnovid 1 mg hard capsules, Empliciti 400 mg powder for concentrate for solution for infusion., Empliciti 300 mg powder for concentrate for solution for infusion., Pomalidomide, VELCADE 3.5 mg powder for solution for injection, Privigen 100 mg/ml s

    Janssen-Cilag International N.V.

    Relapsed or Refractory Myeloma

    phase 3 small molecule active

    1 trial

  19. Psilocybin

    Compass Therapeutics

    Treatment Resistant Depression

    phase 3 small molecule active

    7 trials

  20. Randomized control trial comparison between intra-articular infiltrations of PRP, MFAT, and PRP-MFAT in the treatment of symptomatic knee osteoarthritis.

    ISTA Pharma Limited

    knee osteoarthritis

    phase 3 other active

    1 trial

  21. Rukobia 600 mg prolonged-release tablets

    ViiV Healthcare BV

    Heavily Treatment Experienced Subjects Infected with Multi-drug Resistant (MDR) HIV-1

    phase 3 small molecule active

    1 trial

  22. SYLVANT 400 mg powder for concentrate for solution for infusion, ABIRATERONE ACETATE, AMG 509, ABIRATERONE ACETATE, ENZALUTAMIDE, AMG 509, AMG 509, CABAZITAXEL

    Amgen Technology (Ireland) UC

    Metastatic castration-resistant prostate cancer (mCRPC)

    phase 3 small molecule active

    1 trial

  23. Sildenafil placebo, Remidia, 20 mg, tabletki powlekane

    Cardiol Therapeutics

    Patients with functionally single ventricle (FSV - functionally single ventricle) after Fontan operation. The term "functionally single ventricle" refers to congenital heart defects in which one of the ventricles is not fully developed and/or one of the valves is atresia/hypoplastic as a result, it is not possible to correct the intracardiac defect. Then, there are indications for the Fontan operation, i.e. a palliative procedure - total cavo-pulmonary connection (TCPC). In patients with a functionally single ventricle, more than one operation is necessary to separate the systemic and pulmonary circulation. As a result of these procedures, Fontan circulation is created, which consists in bypassing the right heart chambers and directing the venous blood to the pulmonary artery. This leads to the removal of the right-to-left shunt and improvement of arterial blood saturation and reduction of volume overload of the systemic ventricle. At the same time, there is an increase in systemic venous pressure and a decrease in cardiac output. Low pulmonary resistance in these patients is crucial for maintaining optimal hemodynamic conditions both at rest and especially during exercise. Even a slight increase in pulmonary resistance leads to reduced pulmonary blood flow, reduced initial depression of a single ventricle, and consequently to reduced cardiac output and worsened exercise tolerance. Thus, pulmonary resistance in these patients should be not only normal, but also as low as possible to ensure adequate single ventricular filling and adequate cardiac output. There is evidence that patients with Fontan surgery increase pulmonary resistance over time. The increase in pulmonary resistance in these patients may result from several factors, and above all from the progressive dysfunction of a single systemic ventricle and the lack of a subpulmonary chamber ensuring pulsatile pulmonary flow. Although the Fontan operation in many patients with an univentricular heart is a very good method of palliative treatment, which undoubtedly extends the survival of children born with this heart defect, it also inevitably leads to severe complications developing over the years. Patients after the Fontan operation are also characterized by a significant reduction in exercise capacity, which is observed both in clinical practice in reference centres dealing with patients with congenital heart defects, and in multi-centre studies. Among other things, it was shown that children after the Fontan operation obtained 30% lower values of peak oxygen uptake in the ergospirometric test compared to the control group of healthy children (Amadero P et al., Heart 2018). The reduced exercise capacity of patients and the development of Fontan circulatory complications affect both the quality of life and the prognosis of adult patients with univentricular heart.

    phase 3 small molecule active

    1 trial

  24. Skilarence 120 mg gastro-resistant tablets, MAGNESIUM STEARATE, MICROCRYSTALLINE CELLULOSE

    Institut für biomedizinische Analytik NMR-Imaging GmbH

    Adrenomyeloneuropathy

    phase 3 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources